Topical Application of PPADS Inhibits Complement Activation and Choroidal Neovascularization in a Model of Age-Related Macular Degeneration

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Birke, Kerstin ^a   Lipo, Erion ^a   Birke, Marco T ^a   Kumar Singh, Rajendra ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; COMPLEMENT ACTIVATION; CYTOLYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MITOGENESIS; MOUSE; NONHUMAN; PROTEIN SECRETION; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; UMBILICAL VEIN ENDOTHELIAL CELL;

ADMINISTRATION, TOPICAL; ANIMALS; CHOROIDAL NEOVASCULARIZATION; COMPLEMENT ACTIVATION; COMPLEMENT MEMBRANE ATTACK COMPLEX; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LASERS; MACULAR DEGENERATION; MICE; MICE, INBRED C57BL; PLATELET AGGREGATION INHIBITORS; PYRIDOXAL PHOSPHATE;

EID: 84885166262     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076766     Document Type: Article

References (50)

1. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY, (2012) Age-related macular degeneration. Lancet 379: 1728-1738.
2. Bhutto I, Lutty G, (2012) Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. Mol Aspects Med 33: 295-317.
3. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, et al. (2001) An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 20: 705-732.
4. de Jong PT, (2006) Age-related macular degeneration. N Engl J Med 355: 1474-1485.
5. Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, et al. (2009) Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 116: 2393-2399.
6. Ferrara N, (2010) Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med 16: 1107-1111.
7. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore PA, (2009) An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci U S A 106: 18751-18756.
8. Keane PA, Sadda SR, (2012) Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians. J Ophthalmol 2012: 483034.
9. Brand CS, (2012) Management of retinal vascular diseases: a patient-centric approach. Eye (Lond) 26Suppl 2: S1-16.
10. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, et al. (2008) Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246: 81-87.
11. Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, et al. (2008) Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 86: 372-376.
12. Casten RJ, Rovner BW, (2013) Update on depression and age-related macular degeneration. Curr Opin Ophthalmol 24: 239-243.
13. Goldstein JE, Massof RW, Deremeik JT, Braudway S, Jackson ML, et al. (2012) Baseline traits of low vision patients served by private outpatient clinical centers in the United States. Arch Ophthalmol 130: 1028-1037.
14. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, et al. (2005) Complement factor H polymorphism in age-related macular degeneration. Science 308: 385-389.
15. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, et al. (2005) A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 102: 7227-7232.
16. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, et al. (2005) Complement factor H variant increases the risk of age-related macular degeneration. Science 308: 419-421.
17. Davies A, Lachmann PJ, (1993) Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol Res 12: 258-275.
18. Mullins RF, Dewald AD, Streb LM, Wang K, Kuehn MH, et al. (2011) Elevated membrane attack complex in human choroid with high risk complement factor H genotypes. Exp Eye Res 93: 565-567.
19. Nishiguchi KM, Yasuma TR, Tomida D, Nakamura M, Ishikawa K, et al. (2012) C9-R95X polymorphism in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 53: 508-512.
20. Ebrahimi KB, Fijalkowski N, Cano M, Handa JT, (2013) Decreased membrane complement regulators in the retinal pigmented epithelium contributes to age-related macular degeneration. J Pathol 229: 729-742.
21. Cashman SM, Ramo K, Kumar-Singh R, (2011) A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration. PLoS One 6: e19078.
22. Skals M, Leipziger J, Praetorius HA, (2011) Haemolysis induced by alpha-toxin from Staphylococcus aureus requires P2X receptor activation. Pflugers Arch 462: 669-679.
23. Larsen CK, Skals M, Wang T, Cheema MU, Leipziger J, et al. (2011) Python erythrocytes are resistant to alpha-hemolysin from Escherichia coli. J Membr Biol 244: 131-140.
24. Munksgaard PS, Vorup-Jensen T, Reinholdt J, Soderstrom CM, Poulsen K, et al. (2012) Leukotoxin from Aggregatibacter actinomycetemcomitans causes shrinkage and P2X receptor-dependent lysis of human erythrocytes. Cell Microbiol 14: 1904-1920.
25. Hejl JL, Skals M, Leipziger J, Praetorius HA, (2013) P2X receptor stimulation amplifies complement-induced haemolysis. Pflugers Arch 465: 529-541.
26. Lambrecht G, Friebe T, Grimm U, Windscheif U, Bungardt E, et al. (1992) PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses. Eur J Pharmacol 217: 217-219.
27. Coddou C, Yan Z, Obsil T, Huidobro-Toro JP, Stojilkovic SS, (2011) Activation and regulation of purinergic P2X receptor channels. Pharmacol Rev 63: 641-683.
28. Georgalas I, Papaconstantinou D, Koutsandrea C, Kalantzis G, Karagiannis D, et al. (2009) Angioid streaks, clinical course, complications, and current therapeutic management. Ther Clin Risk Manag 5: 81-89.
29. Ament CS, Zacks DN, Lane AM, Krzystolik M, D'Amico DJ, et al. (2006) Predictors of visual outcome and choroidal neovascular membrane formation after traumatic choroidal rupture. Arch Ophthalmol 124: 957-966.
30. Montero JA, Ruiz-Moreno JM, (2010) Treatment of choroidal neovascularization in high myopia. Curr Drug Targets 11: 630-644.
31. Grossniklaus HE, Kang SJ, Berglin L, (2010) Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res 29: 500-519.
32. Halperin JA, Taratuska A, Nicholson-Weller A, (1993) Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J Clin Invest 91: 1974-1978.
33. Kunchithapautham K, Bandyopadhyay M, Dahrouj M, Thurman JM, Rohrer B, (2012) Sublytic membrane-attack-complex activation and VEGF secretion in retinal pigment epithelial cells. Adv Exp Med Biol 723: 23-30.
34. Walport MJ, (2001) Complement. Second of two parts. N Engl J Med 344: 1140-1144.
35. Walport MJ, (2001) Complement. First of two parts. N Engl J Med 344: 1058-1066.
36. Ford KM, Saint-Geniez M, Walshe T, Zahr A, D'Amore PA, (2011) Expression and role of VEGF in the adult retinal pigment epithelium. Invest Ophthalmol Vis Sci 52: 9478-9487.
37. Lazarus A, Keshet E, (2011) Vascular endothelial growth factor and vascular homeostasis. Proc Am Thorac Soc 8: 508-511.
38. Edwards AO, Ritter R, 3rd, Abel KJ, Manning A, Panhuysen C, et al. (2005) Complement factor H polymorphism and age-related macular degeneration. Science 308: 421-424.
39. Ambati J, Atkinson JP, Gelfand BD, (2013) Immunology of age-related macular degeneration. Nat Rev Immunol 13: 438-451.
40. Sheu SJ, Bee YS, Ma YL, Liu GS, Lin HC, et al. (2009) Inhibition of choroidal neovascularization by topical application of angiogenesis inhibitor vasostatin. Mol Vis 15: 1897-1905.
41. Cloutier F, Lawrence M, Goody R, Lamoureux S, Al-Mahmood S, et al. (2012) Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administration. Invest Ophthalmol Vis Sci 53: 1195-1203.
42. Kiuchi K, Matsuoka M, Wu JC, Lima e Silva R, Kengatharan M, et al. (2008) Mecamylamine suppresses Basal and nicotine-stimulated choroidal neovascularization. Invest Ophthalmol Vis Sci 49: 1705-1711.
43. Bee YS, Sheu SJ, Ma YL, Lin HC, Weng WT, et al. (2010) Topical application of recombinant calreticulin peptide, vasostatin 48, alleviates laser-induced choroidal neovascularization in rats. Mol Vis 16: 756-767.
44. Yafai Y, Yang XM, Niemeyer M, Nishiwaki A, Lange J, et al. (2011) Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats. Eur J Pharmacol 666: 12-18.
45. Iwase T, Oveson BC, Hashida N, Lima e Silva R, Shen J, et al. (2013) Topical pazopanib blocks VEGF-induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit. Invest Ophthalmol Vis Sci 54: 503-511.
46. Robbie SJ, Lundh von Leithner P, Ju M, Lange CA, King AG, et al. (2013) Assessing a novel depot delivery strategy for noninvasive administration of VEGF/PDGF RTK inhibitors for ocular neovascular disease. Invest Ophthalmol Vis Sci 54: 1490-1500.
47. Coddou C, Codocedo JF, Li S, Lillo JG, Acuna-Castillo C, et al. (2009) Reactive oxygen species potentiate the P2X2 receptor activity through intracellular Cys430. J Neurosci 29: 12284-12291.
48. Jarrett SG, Boulton ME, (2012) Consequences of oxidative stress in age-related macular degeneration. Mol Aspects Med 33: 399-417.
49. Wu T, Dai M, Shi XR, Jiang ZG, Nuttall AL, (2011) Functional expression of P2X4 receptor in capillary endothelial cells of the cochlear spiral ligament and its role in regulating the capillary diameter. Am J Physiol Heart Circ Physiol 301: H69-78.
50. Sarman S, Mancini J, van der Ploeg I, Croxatto JO, Kvanta A, et al. (2008) Involvement of purinergic P2 receptors in experimental retinal neovascularization. Curr Eye Res 33: 285-291.